Masuda T, Katsumata S, Isaka M, Serizawa M, et al. Impact of TP53 Co-Mutation on Clinicopathological Features, Prognosis, Recurrence Patterns, and the Efficacy of EGFR-TKI Treatment After Recurrence in Resected Early-Stage EGFR-Mutated Lung Adenocarcinoma. Clin Lung Cancer 2025;26:e374-e381.
PMID: 40410020